We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show

By LabMedica International staff writers
Posted on 02 Aug 2018
Image: The VITROS XT 7600 Integrated System (Photo courtesy of Ortho Clinical Diagnostics).
Image: The VITROS XT 7600 Integrated System (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA), a global in vitro diagnostics company, officially unveiled the VITROS XT 7600 Integrated System at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. Ortho also displayed additional clinical lab and immunohematology analyzers and other solutions at the conference held July 29 - August 2 in Chicago, Illinois, USA. Additionally, the company presented seven scientific posters highlighting the performance of assays that are part of its offerings for sepsis, Chagas, diabetes and other conditions.

Ortho is a global in vitro diagnostics company serving the clinical laboratory and immunohematology communities. The company provides sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories. Ortho's blood typing products for the immunohematology community help ensure that every patient receives safe, right type and right unit of blood.

On display at this year’s AACC was Ortho's latest analyzer to receive CE Mark, the VITROS XT 7600 Integrated System, which combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously. Other products displayed by Ortho at the event included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions and its immunohematology analyzers, ORTHO VISION and ORTHO VISION Max. Visitors at the company’s booth also explored its virtual reality experience LabBuilder, which allows users to re-imagine what is possible by creating a digital lab that fits their needs.

"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS XT 7600, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Thyroid Test
Anti-Thyroid EIA Test

Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
PURITAN MEDICAL